Lei Yang

Lei Yang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
YCYinru Chen
Yinru Chen
WLWanzhen Li
Wanzhen Li
XLXiaofen Liu
Xiaofen Liu
YCYan Chen
Yan Chen
JZJing Zhang
Jing Zhang
LYLei Yang
Lei Yang

15 August 2025 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
JSJie Song
Jie Song
HYHao-Yue Yuan
Hao-Yue Yuan
MWMei-Hua Wang
Mei-Hua Wang
WCWei Chen
Wei Chen
ZDZhuo-Ying Du
Zhuo-Ying Du
LYLei Yang
Lei Yang

18 September 2026 in Brain Informatics
Verified
Journal Article
Open access
PDF file
MWMei-Hua Wang
Mei-Hua Wang
RLRui Li
Rui Li
JFJiang Fang
Jiang Fang
XDXinyu Deng
Xinyu Deng
JZJun Zhang
Jun Zhang
LYLei Yang
Lei Yang
Traumatic brain injury (TBI) is frequently complicated by in-hospital events that contribute to prolonged hospitalization and poor neurological outcomes. T

17 March 2026 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
MWMei-Hua Wang
Mei-Hua Wang
RLRui Li
Rui Li
XDXinyu Deng
Xinyu Deng
JZJun Zhang
Jun Zhang
YGYu Guo
Yu Guo
LYLei Yang
Lei Yang

13 May 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
MWMeihua Wang
Meihua Wang
NLNan-Yang Li
Nan-Yang Li
WCWei Chen
Wei Chen
YFYaxin Fan
Yaxin Fan
WLWan-Zhen Li
Wan-Zhen Li
LYLei Yang
Lei Yang
Background: Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) central nervous system (CNS) infections represent a major therapeutic challenge in neurosurgical patients. Intraventricular or intrathecal polymyxin B sulfate (PMB) is commonly used as salvage therapy but is limited by substantial neurotoxicity. Ceftazidime–avibactam (CZA) exhibits potent in vitro activity against KPC-Kp; however, prospective clinical and pharmacokinetic evidence supporting its use in CNS infections remains limited. Methods: In this prospective, single-centre observational study, adult neurosurgical patients with culture-confirmed KPC-Kp CNS infections admitted to the neurointensive care unit of Huashan Hospital were enrolled. Patients received either intravenous CZA (CZA group, n = 15) or intrathecal/intraventricular PMB-based therapy (PMB group, n = 10). Primary outcomes included clinical cure, microbiological eradication, 28-day mortality, and safety. Therapeutic drug monitoring was performed to determine steady-state plasma and cerebrospinal fluid (CSF) concentrations of ceftazidime, avibactam, and polymyxin B, enabling assessment of CSF penetration and exposure–toxicity relationships. Results: Overall clinical cure and microbiological eradication rates were 68.0% and 84.0%, respectively, with a 28-day mortality of 20.0%. Compared with PMB, CZA was associated with a significantly higher clinical cure rate (86.7% vs. 40.0%, p = 0.024) and a numerically higher eradication rate (93.3% vs. 70.0%). No neurological adverse events occurred in the CZA group, whereas neurological toxicity was observed in 60.0% of PMB-treated patients (p < 0.001). Functional outcomes favoured the CZA group, with lower modified Rankin Scale scores at discharge and at 6 months. Pharmacokinetic analyses demonstrated that steady-state CSF concentrations of ceftazidime and avibactam exceeded commonly accepted pharmacodynamic targets, while markedly elevated PMB CSF concentrations were observed in patients with neurological toxicity. Conclusions: While intravenous CZA showed potentially favourable efficacy and safety compared with local PMB in this cohort, these preliminary findings should be interpreted as hypothesis-generating given the small sample size and non-randomised design. These results provide a rationale for further validation in larger multicentre, randomised controlled trials.